Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Prostatic alpha 1-adrenoceptors and uroselectivity

K E Andersson1, H Lepor, M G Wyllie

  • 1Department of Clinical Pharmacology, Lund University Hospital, Sweden.

The Prostate
|February 15, 1997
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Phosphorylation of the androgen receptor by PIM1 in hormone refractory prostate cancer.

Oncogene·2012
Same author

Outcomes of extremely low risk prostate cancer following radical prostatectomy.

Prostate cancer and prostatic diseases·2011
Same author

Symptomatic and urodynamic responses in patients with reduced or no seminal emission during silodosin treatment for LUTS and BPH.

Prostate cancer and prostatic diseases·2010
Same author

Effects of the selective alpha 1a-adrenoceptor antagonist silodosin on ECGs of healthy men in a randomized, double-blind, placebo- and moxifloxacin-controlled study.

Clinical pharmacology and therapeutics·2010
Same author

Side-specific factors associated with extracapsular extension and seminal vesicular invasion in men undergoing open radical retropubic prostatectomy.

Prostate cancer and prostatic diseases·2009
Same author

Letter from the editors of reviews in urology.

Reviews in urology·2006

Alpha 1-adrenoceptor antagonists are used for lower urinary tract obstruction. This review examines claims of uroselectivity and prostate selectivity for newer agents like tamsulosin.

Area of Science:

  • Pharmacology
  • Urology

Background:

  • Alpha 1-adrenoceptor antagonists are used to treat lower urinary tract obstruction symptoms.
  • Early treatments used non-selective alpha 1- and alpha 2-adrenoceptor antagonists like phenoxybenzamine.
  • Development of selective alpha 1-antagonists (e.g., prazosin) aimed to reduce side effects.

Purpose of the Study:

  • To critically evaluate claims of uroselectivity and prostate selectivity for newer alpha 1-adrenoceptor antagonists.
  • To provide a comprehensive analysis of pre-clinical and clinical data regarding these agents.
  • To define selectivity at different levels: in vitro, in vivo, and clinical.

Main Methods:

  • Comprehensive literature review of pre-clinical and clinical data.
  • Inclusion of studies from international sources, including Japanese literature.

Related Experiment Videos

  • Analysis of drug selectivity across various biological systems.

    • Main Results:

    • Newer alpha 1-adrenoceptor antagonists (alfuzosin, doxazosin, terazosin, tamsulosin) have emerged with claims of enhanced selectivity.
    • The concept of "uroselectivity" and "prostate" selectivity requires careful definition and validation.
    • Selectivity varies depending on the specific alpha 1-adrenoceptor subtype involved.

    Conclusions:

    • Conclusions are drawn within the framework of alpha 1-adrenoceptor subtypes (alpha 1A, 1B, 1D).
    • The clinical relevance of reported selectivity needs further investigation.
    • Understanding subtype selectivity is crucial for optimizing treatment of lower urinary tract obstruction.